As GLP-1 receptor agonist use has expanded, researchers have examined their effects beyond metabolic function — including in female reproductive biology. This overview covers published research on GLP-1 signaling in the context of women’s fertility and reproductive health. This overview specifically addresses glp-1 research and fertility, and related research is indexed on PubMed.
GLP-1 Receptors in Female Reproductive Tissue
GLP-1 receptors have been identified in multiple reproductive tissues: the ovary (particularly granulosa cells and oocytes), endometrium, fallopian tubes, and the hypothalamic-pituitary axis that regulates gonadotropin secretion. This distribution suggests GLP-1 signaling may have physiologically relevant roles in female reproductive function beyond its metabolic effects.
GLP-1 Agonists and PCOS
Polycystic ovary syndrome (PCOS) affects an estimated 8–13% of women of reproductive age and is characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance. The insulin resistance component makes GLP-1 receptor agonists a natural research target in this population.
Multiple small clinical trials and observational studies have examined GLP-1 RA treatment in PCOS. Published findings have reported improvements in: insulin sensitivity, androgen levels (testosterone and DHEAS), menstrual regularity (as a proxy for ovulatory function), and weight — with weight reduction confounding direct hormonal effects. A 2023 systematic review in the journal Human Reproduction found that GLP-1 RAs were associated with improvements in hormonal parameters in women with PCOS, though the evidence was characterized as preliminary due to small study sizes.
Ovarian Function and IVF Research
Research has examined GLP-1R expression in granulosa cells (which surround and support developing oocytes) and investigated whether GLP-1 signaling influences ovarian follicle development and oocyte quality. Animal model data from rodent and bovine models has reported effects of GLP-1 agonists on granulosa cell survival, steroidogenesis, and ovulation.
The clinical question of whether GLP-1 receptor agonists used during IVF cycles affect outcomes is an active area of investigation. Retrospective data has produced mixed results; prospective controlled trials are ongoing as of the current date.
Weight Loss, Fertility, and the Confounding Problem
A central methodological challenge in this research area is disentangling direct GLP-1R effects from the indirect effects of weight loss. Obesity is itself a major cause of hormonal dysregulation, anovulation, and reduced fertility. GLP-1 receptor agonists produce significant weight loss, which independently improves many reproductive parameters. Determining whether GLP-1R agonism has direct reproductive effects — beyond those mediated by weight loss — requires study designs that control for this confound, which are technically difficult to execute.
Preconception Guidance: What Prescribing Information Actually Says
Separate from the mechanistic fertility research discussed above, there is a distinct and clinically important practical question for anyone using an approved GLP-1 receptor agonist while planning pregnancy: current prescribing information for semaglutide advises discontinuation before a planned pregnancy, based on animal reproductive toxicity data showing fetal harm at doses used in those studies and the absence of adequate human safety data during pregnancy; tirzepatide carries a similar caution. Because these medications have relatively long half-lives (semaglutide roughly one week; tirzepatide roughly five days), a single dose remains in circulation for a meaningfully longer period than most conventional medications, which is the basis for the washout period guidance discussed with prescribers before attempting conception. Cited washout timelines have varied across sources (semaglutide recommendations have ranged from roughly 5 weeks to 2 months; tirzepatide guidance has ranged from roughly a month to as long as 3 months in some clinical guidance), reflecting that there isn’t a single universal number in the FDA label itself — this is precisely why the standard clinical recommendation, including from professional bodies like ACOG and the American Diabetes Association, is to discontinue GLP-1 therapy before conception and to confirm the specific timing directly with a prescribing physician rather than rely on any general online guidance, including this article.
What Happens If Conception Occurs While on Therapy
Given the long half-lives discussed above, an unplanned pregnancy occurring shortly after stopping (or while still taking) a GLP-1 receptor agonist is a realistic scenario given how common these medications have become. Current clinical guidance in this situation is to contact the prescribing physician promptly rather than make an independent decision, since management depends on individual factors including gestational timing and dosing history. This is explicitly a discussion for a qualified prescriber and not a question this article, or any general educational resource, is positioned to answer for a specific individual case.
Frequently Asked Questions
How long before trying to conceive should GLP-1 therapy be stopped?
Cited timelines vary across sources and specific medications (commonly ranging from roughly one to three months), and the FDA label does not specify one single universal number — the standard recommendation is to discuss and confirm exact timing directly with a prescribing physician well in advance of attempting conception.
Why do these medications require a longer washout than many other drugs?
Semaglutide and tirzepatide have comparatively long circulating half-lives (roughly one week and five days respectively) by pharmaceutical design — this is the same property that enables their once-weekly dosing schedule, but it also means residual drug remains in the body for a longer window after the last dose than shorter-half-life medications.
Is there established human data on outcomes for pregnancies exposed to GLP-1 receptor agonists?
Human pregnancy safety data remains limited; current guidance is based substantially on animal reproductive toxicity findings and a cautious, unmet-data approach rather than a robust human evidence base, which is exactly why professional guidelines recommend avoiding use during pregnancy rather than relying on reassurance from limited case data.
Explore the GLP-1 Research Hub for additional research summaries and compound profiles.
Educational overview of published research. Not medical advice. Fertility and reproductive health decisions should be made with a qualified healthcare provider.
